EOFlow v Insulet (CoA, 26 February 2026)
| Date | 26 February 2026 |
|---|---|
| Court | CoA |
| Division | Luxembourg (LU) |
| Type of action | Request for a discretionary review (RoP 220.3) |
| Case number(s) | UPC_CoA_34/2026 |
| Registry reference | UPC-COA-0000034/2026 |
| Parties | EOFlow Co., Ltd. v. Insulet Corporation |
Official decision (PDF) · UPC registry entry
Dhenne Avocats represents claimants and defendants in European patent disputes before the Unified Patent Court, including the Paris divisions.
Dhenne Avocats · 10 October 2026
Our analysis
Summary
By order of 26 February 2026 (UPC_CoA_34/2026), the standing judge of the Court of Appeal dismissed as inadmissible EOFlow’s request for discretionary review and its auxiliary request for leave to appeal. Both targeted the Milan Central Division’s order of 4 December 2025, which set penalty payments of EUR 150,000 for non-compliance with provisional measures (EP 4 201 327) and ordered EOFlow to pay EUR 10,000 in costs. The order confirms that review under Rule 220.3 presupposes a refusal of leave by the Court of First Instance, sought within the 15-day period.
Question
Can a party that failed to seek leave to appeal from the first instance in time obtain discretionary review or, failing that, leave to appeal from the Court of Appeal itself?
Decision
Discretionary review is available only where the first instance has refused leave. EOFlow did not request leave within 15 days, and the Court left open the position where the first instance fails to rule within that period (paragraph 16). Total v Texas Instruments is not comparable: nothing prevented EOFlow, which was represented by counsel, from seeking leave (paragraph 17). Article 73(2)(b) UPCA and Rule 220.2 leave the decision on leave to the court that issued the order. The Court of Appeal deals with leave only within an admissible discretionary review (paragraph 18). There was no need to rule on the confidentiality requests at this stage (paragraph 19).
Key points for practice
- For orders falling under Rule 220.2, leave must be sought from the first instance within 15 days, an argument based on an ambiguous note on remedies in the order does not cure a missed deadline, and the Court of Appeal will not grant leave itself (paragraphs 16 to 18).
Provisions applied
- Agreement on a Unified Patent Court
- Arts 58 and 73(2)(b)
- Rules of Procedure
- Rules 220.2, 220.3, 262, 262.2, 262A and 354.4
- Case law cited
- Suinno v Microsoft, Court of Appeal, 9 October 2024, Total v Texas Instruments, Court of Appeal, 14 January 2025, Insulet v A. Menarini Diagnostics, Court of Appeal, 9 January 2025, EOFlow v Insulet, Court of Appeal, 4 February 2026
Related decisions
Prepared by Dhenne Avocats from the official decision, consulted on 10 October 2026. The database is updated every week, on Friday. Only the official text is authoritative.
Going further
Lexicon: UPC Court of Appeal, Supplementary protection certificate (SPC), Biosimilar medicinal product, Launch at risk.
Dhenne Avocats blog: UPC Appeals: What the Numbers Show, Pharmaceutical patents and the UPC: is the Court hostile to them?.
Publications by Matthieu Dhenne: The Launch Letter: How Generics and Biosimilars Should Write to Avoid UPC Urgency (Kluwer Patent Blog).
Source and translations
- Official source
- Unified Patent Court registry link recorded in the record
- Original language
- not recorded
- Translation available
- no translation recorded the firm’s French record is a summary, not a translation
- Date checked
- not recorded
Follow this case
Proceedings, related decisions, appeals, parties and patents as recorded in the registry and in the Dhenne Avocats corpus. Each link states its source.
Parties
- defendantInsulet Corporation26 decisions in the corpusFollow this party
- claimantEOFlow Co., Ltd.22 decisions in the corpusFollow this party
Decisions in the same proceedings and documented appeals
What the record states
- Nature of the act
- Request for a discretionary review (RoP 220.3)
- Outcome (Dhenne Avocats summary)
- La demande de réexamen discrétionnaire est irrecevable faute de demande d'autorisation présentée à la première instance dans les 15 jours, et la cour d'appel ne peut accorder elle-même l'autorisation d'appel, réservée par l'article 73, paragraphe 2, sous b), de l'Accord à la juridiction qui a rendu l'ordonnance.
- Appeal
- Decision of the Court of Appeal.
- Instance
- Court of Appeal decision.
Patents mentioned
EP 4 201 327mentioned in: Dhenne Avocats analysis Follow this patent
Related decisions cited in the analyses
- EOFlow v Insulet (CoA, 4 February 2026) cited in this record
- Insulet v EOFLOW (CFI, 4 December 2025) cited in this record
- TOTAL SEMICONDUCTOR v Texas Instruments Deutschland (CoA, 14 January 2025) cited in this record
- Insulet v A. Menarini Diagnostics (CoA, APL_64383/2024, 9 January 2025) cited in this record
- Suinno Mobile & AI Technologies Licensing v Microsoft (CoA, 9 October 2024) cited in this record
- Speed Care Mineral v Teleflex Life Sciences II (CoA, 10 June 2026) cites this decision
Patents and standards
| Publication | Role in the dispute | Family | Standard and declaration | Pool | Sources |
|---|---|---|---|---|---|
EP 4 201 327Fluid delivery device with transcutaneous access tool, insertion mechanism and blood glucose monitoring for use therewith recorded proprietor: Insulet Corp | Mentioned in the analysis (role not qualified) Also mentioned in 25 other decision(s): EOFLOW v Insulet (CFI, 22 July 2025) · EOFLOW v Insulet (CoA, 18 March 2026) · EOFlow v Insulet (CoA, 4 February 2026) · EOFlow v Insulet (CoA, 29 January 2026) · Herbert Smith Freehills Kramer (applicant) in Insulet v EOFLow (CoA, 2 · Insulet v EOFLOW (CFI, 15 October 2025) · EOFLOW v Insulet (CFI, ORD_26828/2025, 5 June 2025) · EOFLOW v Insulet (CFI, 28 May 2025) | not recorded | not recorded | not recorded | Espacenet · European Patent Register existence and title of the publication checked on 30 October 2026 (Google Patents, Espacenet and Register links are not checked automatically) mentioned in: Dhenne Avocats analysis |
Receive an alert
Weekly summary of new records and substantive updates matching what you follow. Address confirmed by email, unsubscribe at any time, one email per week even where several of your follows match.